Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03798626 · ClinicalTrials.gov registry record · Phase 1
Gevokizumab With Standard of Care Anti-cancer Therapies for Metastatic Colorectal, Gastroesophageal, and Renal Cancers
A Phase 1 study, sponsored by Novartis Pharmaceuticals.
- Completed
- Registry status
- Phase 1
- Development phase
- 167
- Enrollment target
NCT03798626 is a Phase 1 study that has completed, run by Novartis Pharmaceuticals. The registered enrollment target is 167 participants.
The verdict
NCT03798626, a Phase 1 study, has completed, sponsored by Novartis Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 167 participants
- Enrollment target
Study Summary
This study will determine the pharmacodynamically-active dose of gevokizumab and the tolerable dose of gevokizumab in combination with the standard of care anti-cancer therapy in patients with metastatic colorectal cancer, metastatic gastroesophageal cancer and metastatic renal cell carcinoma, and the preliminary efficacy of gevokizumab in combination with the SOC anti-cancer therapy in subjects with mCRC and mGEC.
Interventions
- DRUG Bevacizumab
- DRUG Ramucirumab
- DRUG FOLFIRI
- DRUG Modified FOLFOX6
- DRUG Gevokizumab
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 167 participants |
| Start Date | 2019-05-22 |
| Est. Completion | 2025-02-05 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03798626
The ClinicalTrials.gov registry entry for NCT03798626 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 167 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Novartis Pharmaceuticals, which has 1,375 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which Bevacizumab is the first listed.
NCT03798626 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03798626 about?
NCT03798626 is a clinical study titled "Gevokizumab With Standard of Care Anti-cancer Therapies for Metastatic Colorectal, Gastroesophageal, and Renal Cancers". This study will determine the pharmacodynamically-active dose of gevokizumab and the tolerable dose of gevokizumab in combination with the standard of care anti-cancer therapy in patients with metastatic colorectal cancer, metastatic gastroesophageal cancer and metastatic renal cell carcinoma, and t...
What is the current status of trial NCT03798626?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 167 participants. The study started on 2019-05-22. Estimated completion is 2025-02-05.
What interventions are being tested in trial NCT03798626?
The interventions under investigation include: Bevacizumab (DRUG), Ramucirumab (DRUG), FOLFIRI (DRUG), Modified FOLFOX6 (DRUG), Gevokizumab (DRUG).
Who is sponsoring clinical trial NCT03798626?
This trial is sponsored by Novartis Pharmaceuticals, which has 1,375 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.